

## Treatment of hyperferritinemia

Melanie D. Beaton,\* Paul C. Adams\*

\* University of Western Ontario, London Health Sciences Centre, Department of Medicine, Division of Gastroenterology. Canada.

### ABSTRACT

Elevated serum ferritin, or hyperferritinemia, is a common finding on routine bloodwork and often prompts referral for further evaluation. In the following review, we outline the various causes of hyperferritinemia and point out that, in the majority of cases, this does not represent true iron overload. Despite much research interest in this area, the precise mechanism of hyperferritinemia and its impact on disease severity in various clinical conditions continues to be debated. While some research suggests that iron reduction in cases of hyperferritinemia is of benefit, the decision to treat such patients should be individualized, and may be influenced by the presence of other features of iron overload.

**Key words.** Iron overload. Ferritin. Liver Disease. Therapy.

### INTRODUCTION

Serum ferritin is the most frequently requested measure of body iron status and one of the most frequently requested laboratory tests in both primary care and referral settings.<sup>1</sup> Ferritin is the cellular storage protein for iron and is able to store up to 4,500 atoms of iron with much of this iron accessible for metabolic needs. The normal adult total body iron content is approximately 3-4 g. On average, 2.5 g is contained within hemoglobin in circulating red blood cells and developing erythroblasts, 400 mg in iron containing proteins, 3-7 mg in the form of transferrin-bound iron and the remainder stored as ferritin or hemosiderin.

The human body has no means of excreting excess iron. Only a very small amount, average 1 mg, leaves the body each day via loss in sweat, shed skin cells and some gastrointestinal loss. The vast majority (20-25 mg) is efficiently recycled from the breakdown of senescent red blood cells within the reticuloendothelial system. The average Western male consumes 1-2 mg of heme iron and 10-15 mg of non-heme iron each day. Roughly 30% of heme iron

is absorbed and 10% of non-heme iron, totaling 1-2 mg/day maintain iron balance.

Ferritin is a reliable surrogate marker of body iron stores with low values providing absolute evidence of reduced reticuloendothelial iron stores.<sup>2</sup> Elevated ferritin levels however, are far less specific for systemic iron overload. Ferritin is an acute phase reactant, defined as a protein whose serum concentration increases or decreases by at least 25 percent during inflammatory states.<sup>3</sup>

The magnitude of the problem of hyperferritinemia was evidenced by the results of the HEIRS study.<sup>4</sup> This population based screening study sought to determine the incidence of hereditary hemochromatosis (HH) in a large multi-ethnic, multi-racial primary care setting within North America. Of the 101,168 participants screened for iron overload and *HFE* mutations, 5.9% of Caucasian subjects and 19% of Asian subjects were found to have hyperferritinemia. Whereas 0.44%, (approximately 1 in 200) of Caucasians were found to be homozygous for the C282Y mutation only 0.00004% (1 in 25,000) Asians were homozygous. This important study demonstrated that hyperferritinemia is very common and that in the majority of individuals it is due to conditions other than HH.

### WHAT IS A NORMAL FERRITIN?

When approaching the diagnosis of hyperferritinemia one must first determine what a "normal" value is. Reference ranges vary across laboratories due

---

**Correspondence and reprint request:** Dr. Paul C. Adams  
University Hospital, 339 Windermere Rd. London, Ontario, Canada N6A 5A5.  
Ph.: 519 685 8500, Ext. 35375. Fax: 519 663 3549  
E-mail: padams@uwo.ca

*Manuscript received: December 01, 2011.*  
*Manuscript accepted: December 02, 2011.*

to differences in analytical techniques and reference populations. Age and sex are also important determinants with lower cutoffs acceptable for women due to increased iron loss secondary to menses, pregnancy and lactation. The HEIRS study defined that a serum ferritin concentration  $> 300 \mu\text{g/L}$  in men and  $> 200 \mu\text{g/L}$  in women was elevated. However, if the reference range had been determined from the HEIRS study as mean  $\pm$  two standard deviations, the upper limit of the reference range would have been significantly  $> 300 \mu\text{g/L}$ . Generally levels between 30-300  $\mu\text{g/L}$  for men and 15-200  $\mu\text{g/L}$  for women are considered normal, which reflects the significant variation in serum ferritin present in the population.

### NOT ALL HYPERFERRITINEMIA REPRESENTS IRON OVERLOAD

Hyperferritinemia can be caused by a variety of systemic conditions including infection, neoplasm and chronic or acute inflammation (Table 1). In the setting of C282Y-linked hemochromatosis, ferritin is a sensitive marker of iron overload and is used to monitor response to treatment. However, ferritin elevations may also be commonly seen in a number

of other liver diseases including alcoholic and nonalcoholic steatohepatitis (NASH), viral hepatitis and almost any cause of acute liver injury will be accompanied by ferritin elevation.

Elevated serum ferritin levels are increasingly being recognized in patients with features of the metabolic syndrome and insulin resistance. This is particularly relevant in the setting of NASH, which is the hepatic manifestation of the metabolic syndrome. Whether hyperferritinemia itself is associated with more severe liver disease in NASH patients remains controversial. As well, whether targeting high serum ferritin for treatment via phlebotomy improves liver disease is as yet somewhat uncertain.

One of the greatest challenges facing physicians dealing with patients with hyperferritinemia is determining whether the elevated ferritin truly represents iron overload. As stated previously, hyperferritinemia can be seen in a wide variety of clinical conditions, many of which do not cause iron overload. The cause of elevated serum ferritin is usually the result of increased ferritin synthesis from acquired or genetic disorders, or increased release of ferritin from damaged cells (Table 2).

**Table 2.** Mechanisms of hyperferritinemia in various disorders.

**Table 1.** Causes and spectrum of hyperferritinemia.

- Serum ferritin 300-1,000  $\mu\text{g/L}$ .
  - Metabolic syndrome/NAFLD.
  - Daily alcohol consumption.
  - Systemic inflammation.
  - Early hemochromatosis.
  - Malignancy.
  - Unknown.
- Serum ferritin 1,000-5,000  $\mu\text{g/L}$ .
  - Hemochromatosis.
  - Aceruloplasminemia.
  - Ferroportin mutations.
  - Hereditary-hyperferritinemia cataract syndrome (HHCS).
  - Alcoholic liver disease.
  - Viral hepatitis.
  - Secondary iron overload.
    - Transfusion related.
    - Ineffective erythropoiesis.
- Serum ferritin  $> 10,000 \mu\text{g/L}$ .
  - Still's disease.
  - Histiocytosis.
  - Fulminant hepatic failure.

- Increased ferritin synthesis:
  - *HFE* and other types of hemochromatosis.
  - Anemias (heritable and acquired) associated with ineffective erythropoiesis.
  - Aceruloplasminemia.
  - Iron overload secondary to blood transfusion or parenteral iron administration.
- Increased ferritin release from injured cells:
  - Hepatic steatosis and steatohepatitis (alcoholic and nonalcoholic).
  - Chronic viral hepatitis.
  - Massive liver necrosis (ie. due to sepsis, acute hepatitis or toxic injury).
  - Autoimmune and rheumatologic disorders.
  - Acute and chronic infections.
  - Splenic infarction.
- Increased apoferritin (or L ferritin) synthesis or secretion:
  - Chronic ethanol ingestion.
  - Malignancy (malignant histiocytosis, carcinomas of lung, breast, ovary, kidney; lymphoma, liposarcoma).
  - Gaucher disease.
  - Reactive histiocytosis.
  - Hereditary hyperferritinemia-cataract syndrome (HHCS).

In order to determine the cause of ferritin elevation, the clinical setting can be very helpful. Patients with a history of chronic alcohol ingestion or features of the metabolic syndrome (obesity, insulin resistance, dyslipidemia and hypertension) often present with hyperferritinemia. Similarly, patients with chronic inflammatory conditions, renal insufficiency, malignancy and marrow failure may present in a similar manner. In each of these groups ferritin elevation is typically moderate (< 1,000 µg/L) and transferrin saturation (TS) is normal. Systemic iron overload is typically not present and the approach to treating these patients relies on identifying and treating the underlying cause appropriately. A recent review of causes of hyperferritinemia in patients referred to a tertiary care center for evaluation of elevated serum ferritin revealed that causes other than *HFE*-linked hemochromatosis were found in more than one-half of cases<sup>5</sup> (Table 3).

In patients whom have elevated serum liver enzymes in addition to hyperferritinemia, the diagnostic approach should include genetic testing for HH. Whereas the majority of patients with HH will have concomitant elevation of TS this is not always the case. It has been shown that serum iron indices demonstrate diurnal variation and that TS exhibits significant within-person biological variability which limits its usefulness as an initial screening test for HH.<sup>6,7</sup> Transferrin satu-

ration is a calculated value which represents the quotient of the serum iron level divided by one of the following: total iron binding capacity; unsaturated iron-binding capacity + serum iron concentration; or serum transferrin concentration multiplied by a constant. The fact that determination of TS is a two-step process, relying on the measurement of a number of other variables may explain some of its variability. Liver disease can occasionally cause low serum transferrin concentrations which may lead to increased TS without iron overload.

### ATTEMPTS TO FIND A BETTER FERRITIN TEST

There are biochemical variations in the types of ferritin circulating in the human plasma. Tissue ferritins differ from serum ferritin in that they are typically glycosylated.<sup>8</sup> Serum ferritin is a secreted protein, whereas tissue ferritins leak from damaged cells. Ferritin can differ in H and L subunits and in the amount of iron carried per molecule.<sup>9</sup> These differences can be determined by isoelectric focusing and other analytical methods but they have not been widely used to differentiate iron overload from a ferritin related to inflammation.<sup>10</sup> The use of surrogate markers; such as CRP for inflammation or GGT for alcohol have been used and are generally only helpful if elevated.

**Table 3.** Clinical assessment of the cause of the elevated serum ferritin. Iron overload more likely-C282Y homozygote, Transferrin saturation elevated, Ferritin rising over time, Family history of iron overload.

Iron overload less likely-Modest ferritin elevation (< 1,000 µg/L), normal transferrin saturation, underlying liver disease or inflammation, daily alcohol consumption, obesity.

**Diagnostic assessment for iron overload.** *HFE* genotyping, MRI scan, liver biopsy, trial of phlebotomy.

#### Phlebotomy treatment for an elevated serum ferritin

##### Pro -

- Normalization of serum ferritin may reduce liver iron and possible liver injury.
- Improvements in insulin resistance and prevention of vascular disease.
- Patients are reassured as numbers normalize.
- Blood donor pool may increase.
- The most compelling indication is in the C282Y homozygote where iron overload and liver injury secondary to iron overload are clearly established.

##### Con -

- A large number of patients without iron overload will have phlebotomy.
- Iron deficiency anemia can occur in this setting.
- Treatment reinforces a diagnosis of iron overload which may not be present.
- Phlebotomy treatment requires resources and health care systems may have higher priorities.

## AIDS IN DETERMINING WHETHER HYPERFERRITINEMIA MEANS IRON OVERLOAD

Transferrin saturation elevation is central to the pathogenesis of iron loading in HH. Elevated TS results in part from increased iron absorption, and increased iron release from macrophages into plasma. Our centre represents a diverse, tertiary care population. We recently evaluated the correlation between serum TS and liver iron concentration (LIC) in a large sample of patients with and without iron overload. This demonstrated that although elevated TS was often seen in the setting of iron overload, there are a significant number of patients, 44/191 (23%) in this cohort, with an elevated ferritin and normal TS that have an elevated LIC.<sup>11</sup> It was concluded that a normal TS should not be used to exclude the diagnosis of hemochromatosis, but that both TS and serum ferritin should be used together to guide further investigations such as *HFE* genetic testing and/or liver biopsy.

*HFE* genetic testing is often part of the evaluation of hyperferritinemia. Some *HFE* C282Y homozygotes, and less commonly *HFE* H63D homozygotes and compound heterozygotes (*HFE* C282Y/H63D) develop iron overload.<sup>4</sup> Additional mutations in other iron related genes such as hemojuvelin, hepcidin, ferroporin and transferrin receptor 2 are recognized, but as yet, there is no widely available commercial test for these mutations.<sup>12</sup>

Liver biopsy has long been considered the gold standard in evaluating hepatic iron overload and also allows for assessment of concomitant liver disease. However, sampling error is of concern, as a single biopsy represents only 1/50,000th of the liver.<sup>13</sup> Studies of paired biopsies have shown that significant variability can occur between different regions of the liver.<sup>14</sup> An indirect mode of measuring liver iron content is MRI which relies on the paramagnetic properties of storage iron (ferritin and hemosiderin). MRI has shown promise in the accurate, non-invasive measurement of liver iron and as a means of assessing response to therapy for iron overload.<sup>15,16</sup>

## DOES HYPERFERRITINEMIA HAVE AN ADVERSE EFFECT ON HEALTH?

In recent years there has been a great deal of interest regarding the relationship between markers of inflammation and health outcomes. It is now well recognized that activation of inflammatory mediators

plays a significant role in the pathogenesis of many disease processes that had previously been thought to be unrelated to inflammation. These include type 2 diabetes (DM2), obesity and other conditions comprising the metabolic syndrome (MS). As well there is increasing evidence supporting the role of inflammation in vascular disease.

As stated previously, hyperferritinemia is considered an acute phase reactant and as such is elevated in states of systemic inflammation. A number of studies have evaluated the association of hyperferritinemia with disease risk and outcome. Two recent large, population based studies found that high serum ferritin levels are associated with an increased risk of MS and DM2.<sup>17,18</sup> Importantly, this increased risk was present among non-obese adults, a group whom would not normally be considered at significant risk for these conditions.

There is also some evidence to support a link between excess iron and malignancy, specifically hepatocellular carcinoma (HCC). The increased risk of HCC is well recognized in patients with HH.<sup>19</sup> Even in the absence of HH, individuals with excess liver iron have a higher risk of HCC.<sup>20</sup>

The relationship between hyperferritinemia and vascular disease has also been supported by recent studies. A cohort of otherwise healthy young men was evaluated to determine whether elevated serum ferritin was associated with decreased levels of cardiovascular fitness (CVF).<sup>21</sup> Interestingly, serum ferritin levels > 150 µg/L, which is lower than what is normally considered to be elevated, were associated with poorer CVF. Additional studies have examined the relationship between ferritin levels and peripheral artery disease (PAD), concluding that hyperferritinemia is associated with the presence of PAD, and in one study was associated with an increased risk of mortality from PAD.<sup>22,23</sup>

Likely the area of greatest interest regarding a potential relationship between hyperferritinemia and disease is in the setting of nonalcoholic fatty liver disease (NAFLD). Support for this comes from the results of large, population based studies. In the Nurse's Health Study of over 30,000 healthy women, it was concluded that elevated serum ferritin was associated with an increased risk of type 2 diabetes.<sup>24</sup> Similar results were noted in cohort of over 6,000 patients participating in the Third National Health and Nutrition Examination Survey (NHANES III) where the metabolic syndrome was significantly more common in those with elevated serum ferritin.<sup>25</sup> A recent study demonstrated that elevated serum ferritin was associated with

worsened histologic activity of NAFLD and was an independent predictor of advanced hepatic fibrosis.<sup>26</sup> The term “dysmetabolic iron overload syndrome” has even been coined to describe this subgroup of NAFLD patients.

Studies have been published regarding the potential pathophysiologic role of iron in NAFLD.<sup>27,28</sup> One widely supported view is that iron accumulation leads to increased oxidative stress and lipid peroxidation, both of which are central to the pathophysiology of NAFLD. Iron is capable of catalysing the formation of reactive oxygen (ROS) species and a number of studies have demonstrated that hepatic iron loading leads to oxidative damage.<sup>29,30</sup> Hepatic stellate cells can be activated by ROS and thus, by this mechanism, iron may induce fibrogenesis.<sup>31</sup> However, most patients with an elevated ferritin with NASH have a normal liver iron concentration which does not support the theory of iron overload leading to oxidative stress.

### ARE WE TREATING DISEASE, PREVENTING DISEASE OR TREATING A NUMBER?

These associations beg the question that if hyperferritinemia is associated with a particular disease state, then does treating hyperferritinemia improve outcomes in such conditions? Unfortunately, the answer to this question is not entirely clear.

A large multicenter, randomized controlled trial was conducted evaluating iron reduction (phlebotomy) as a treatment for patients with symptomatic but stable PAD.<sup>32</sup> A total of 1,277 patients were randomized to either phlebotomy or control. No significant differences were noted between the two groups for either the primary outcome of all-cause mortality or secondary outcome of death plus nonfatal myocardial infarction and stroke. However, a more recent study by this same group has suggested that a lower iron burden may improve survival and prevent or delay nonfatal myocardial infarction and stroke.<sup>33</sup>

The therapeutic role of iron depletion in patients with liver disease may be somewhat more promising. Stainable iron in hepatocytes and portal tracts has been shown to be a predictor of disease progression in hepatitis C, including HCC and death.<sup>34</sup> This may be a sequelae of liver disease severity rather than a cause. Iron depletion has also been suggested to lower the risk of HCC in these patients.<sup>35</sup>

Iron excess in the setting of NAFLD and the MS is an area of significant research interest. Whereas

HCC is a rare complication of cirrhosis due to NAFLD, like hepatitis C, there is some evidence suggesting that hepatic iron deposition increases the risk of this tumor.<sup>36,37</sup> Removal of iron by phlebotomy has been shown to decrease markers of oxidative stress and levels of TGF- $\beta$ 1, a known stimulant of stellate cell proliferation and fibrogenesis.<sup>38</sup> Some studies of iron reduction therapy have shown improvement in transaminases and metabolic indices such as insulin resistance. However, its impact on hepatic steatohepatitis is largely unknown.<sup>39-41</sup> A prospective study of phlebotomy evaluating pre and post liver histology is currently underway at our center in order to address this important question (NCT00641524).

### IS THERE A RATIONALE FOR PHLEBOTOMY IF IT IS NOT LIKELY TO BE IRON OVERLOAD?

Unfortunately there is still not an absolute answer to this question. The short answer is likely to be no, but as discussed in previous sections of this review, the area is still not fully understood.

Whereas the role of phlebotomy remains controversial in the absence of true iron overload, phlebotomy is likely a reasonable course of action in those patients with demonstrable iron excess. It is clear that iron excess cannot be accurately diagnosed based solely on elevated serum ferritin. It is our recommendation that the presence of tissue iron deposition be confirmed by at least one of the following modalities; iron staining on liver biopsy, measurement of liver iron concentration (LIC) or alternatively, MRI which offers an accurate, noninvasive alternative to liver biopsy. In cases where iron excess is confirmed in the setting of high ferritin, research to date supports a beneficial effect of iron reduction therapy.

Support for this approach comes from preliminary results of our prospective trial of phlebotomy in NAFLD patients. Whereas 64% had an elevated serum ferritin, only 8% had an elevated LIC (defined as  $> 36 \mu\text{mol/g}$ ). The ratio of serum ferritin to liver iron is much higher in NAFLD than that seen in HH. This suggests that a component of the serum ferritin seen in NAFLD is a reaction to inflammation.

### EMPIRICAL PHLEBOTOMY AND AREAS OF UNCERTAINTY

Many patients (and physicians) express alarm at the news of an elevated serum ferritin. The initial

step in the management should be to point out to the patient that there are many causes of an elevated ferritin and iron overload is not the most likely cause in the general population where inflammation, obesity and alcohol would be more likely causes. It may also be helpful to point out that an elevated serum ferritin is extremely common and that ferritin elevations  $< 1,000 \mu\text{g/L}$  are considered modest. Many patients seem determined to die with normal lab test results and are enthusiastic about phlebotomy therapy. These patients should be encouraged to be voluntary blood donors but often are ineligible because of co-morbid diseases and medications. To initiate phlebotomy therapy in the large numbers of patients with an elevated ferritin is resource intensive and the feasibility will depend on the health care system. Many patients enjoy phlebotomy therapy and report an improvement in fatigue and there may be a psychosocial support component to this treatment. A number of areas of uncertainty remain in this clinical setting. If the ferritin elevation is considered to be inflammatory in nature, why does it decrease with phlebotomy? If the liver iron concentration is normal in most of these patients, how does phlebotomy decrease oxidative stress? Could there be other additional medical benefits of phlebotomy unrelated to iron or ferritin?

## CONCLUSIONS

Hyperferritinemia is very common and mild elevations (300-1,000  $\mu\text{g/L}$ ) are frequent in clinical practice. A careful clinical assessment, including a detailed history for alcohol consumption as well as metabolic risk factors (obesity, DM2, dyslipidemia and hypertension) will reveal the cause in many individuals. While the cause of hyperferritinemia is not fully understood in these conditions, evidence to date suggests that inflammation plays a role and that in many cases significant hepatic iron deposition is absent. Based on the preliminary results of our study of phlebotomy in NAFLD we suggest that the currently accepted reference ranges for serum ferritin in healthy adults may be inappropriate in this group and investigations, such as liver biopsy, for iron overload in NAFLD patients with ferritin  $< 1,000 \mu\text{g/L}$  is low yield.

Among patients with demonstrated hepatic iron deposition, the benefit of phlebotomy is well established in HH. Evidence suggests that this therapeutic approach may be beneficial in a number of other conditions including NAFLD. However, this has not yet been confirmed by prospective pre and

post phlebotomy biopsy data. As well, the mechanism by which disease improvement may occur with phlebotomy is not fully understood. Additional studies are clearly needed to further define the role of ferritin in disease.

## ABBREVIATIONS

- HH: hereditary hemochromatosis.
- NASH: nonalcoholic steatohepatitis.
- TS: transferrin saturation.
- LIC: liver iron concentration.
- DM2: type 2 diabetes mellitus.
- MS: metabolic syndrome.
- HCC: hepatocellular carcinoma.
- CVF: cardiovascular fitness.
- PAD: peripheral artery disease.
- NAFLD: nonalcoholic fatty liver disease.
- ROS: reactive oxygen species.

## REFERENCES

1. Ogilvie C, Fitzsimons K, Fitzsimons E. Serum ferritin values in primary care: are high values overlooked? *J Clin Pathol* 2010; 63: 1124-6.
2. Zanella A, Gridelli L, Berzuini A, Colotti MT, Mozz F, Milani S, Sirchia G. Sensitivity and predictive value of serum ferritin and free erythrocyte protoporphyrin for iron deficiency. *J Lab Clin Med* 1989; 113(1): 73.
3. Kushner I. The phenomenon of the acute phase response. *Ann N Y Acad Sci* 1982; 389: 39.
4. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, Dawkins FW, et al. Hemochromatosis and iron-overload screening in a racially diverse population. *N Engl J Med* 2005; 352: 1769-78.
5. Wong K, Adams PC. The diversity of liver diseases among outpatient referrals for elevated serum ferritin. *Can J Gastroenterol* 2006; 20(7): 467-470.
6. Adams PC, Reboussin DM, Leいendecker-Foster C, Moses G, McLaren GD, McLaren CE, Dawkins FW, et al. Comparison of the unsaturated iron binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101,168 participants in the HEIRS study. *Clin Chem* 2005; 51: 1048-51.
7. Adams PC, Reboussin DM, Press RD, Barton JC, Acton RT, Moses GC, Leいendecker-Foster C, et al. Biological variation of transferrin saturation and unsaturated iron-binding capacity. *Am J Med* 2007; 120(11): 999.e1-7.
8. Powell LW, Alpert E, Isselbacher KJ, Drysdale JW. Human isoferritins: organ specific and apoferritin distribution. *Br J Haematol* 1975; 30(1): 47-55.
9. Arosio P, Ingrassia R, Cavadini P. Ferritins: a family of molecules for iron storage, antioxidation and more. *Biochim Biophys Acta* 2009; 1790(7): 589-99.
10. Herbert V, Jayatilleke E, Shaw S, et al. Serum ferritin iron, a new test, measures human body iron stores unconfounded by inflammation. *Stem Cells* 1997; 15(4): 291-6.
11. Adams PC, Beaton MD. Transferrin saturation as a predictor of hepatic iron overload. *Liver Int* 2011; 31(2): 272-3.
12. Pietrangelo A. Hereditary hemochromatosis: a new look at an old disease. *N Eng J Med* 2004; 350: 2383-97.

13. Campbell MS, Reddy KR. Review article: the evolving role of liver biopsy. *Aliment Pharmacol Ther* 2004; 20: 249-59.
14. Merriman RB, Ferrell LD, Patti MG, Weston SR, Pabst MS, Aouizerat BE, Bass NM. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. *Hepatology* 2006; 44(4): 874-80.
15. Sirlin CB, Reeder SB. Magnetic resonance imaging quantification of liver iron. *Magn Reson Imaging Clin N Am* 2010; 18: 359-81.
16. Beddy P, McCann J, Ahern M. MRI assessment of changes in liver iron deposition post-venesection. *Eur J Radiol* 2011; 80(2): 204-7.
17. Yoo KD, Ko SH, Park JE, Ahn YB, Yim HW, Lee WC, Park YM. High serum ferritin levels are associated with metabolic risk factors in non-obese Korean young adults: Korean National Health and Nutrition Examination Survey (KNHANES) IV. *Clin Endocrinol (Oxf)* 2011 [Epub ahead of print].
18. Lee BK, Kim Y, Kim YI. Association of serum ferritin with metabolic syndrome and diabetes mellitus in the South Korean general population according to the Korean National Health Nutrition Examination Survey 2008. *Metabolism* 2011; 60(10): 1416-24.
19. Beaton MD, Adams PC. Prognostic factors and survival in patients with hereditary hemochromatosis and cirrhosis. *Can J Gastroenterol* 2006; 20(4): 257-60.
20. Turlin B, Juguet F, Moirand R, Le Quileuc D, Loreal O, Campion JP, Launois B, et al. Increased liver iron stores in patients with hepatocellular carcinoma developed in a noncirrhotic liver. *Hepatology* 1995; 22: 446-50.
21. Mainous AG, Diaz VA. Relation of serum ferritin level to cardiovascular fitness among young men. *Am J Cardiol* 2009; 103(1): 115-8.
22. Menke A, Fernandez-Real JM, Munter P, Guallar E. The association of biomarkers of iron status with peripheral arterial disease in US adults. *BMC Cardiovasc Disord* 2009; 3(9): 34.
23. Depalma RG, Hayes VW, Chow BK, Shamayeva G, May PE, Zacharski LR. Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial. *J Vasc Surg* 2010; 51(6): 1498-503.
24. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. *JAMA* 2004; 129(6): 711-7.
25. Juhn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. Adults. *Diabetes Care* 2004; 27(10): 2422-8.
26. Kowdley KV, Belt P, Wilson LA, Yeh MA, Neuschwander-Tetri BA, Chalasani N, Sanyal AJ, et al. Elevated serum ferritin is an independent predictor of histologic severity and advanced fibrosis among patients with nonalcoholic fatty liver disease. *Hepatology* 2012; 55: 77-85.
27. Bozzini C, Girelli D, Olivieri O, Martinelli N, Bassi A, De Matteis G. Prevalence of body iron excess in the metabolic syndrome. *Diabetes Care* 2005; 28: 2061-3.
28. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Gu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. *JAMA* 2004; 291: 711-7.
29. Ramm GA, Ruddell RG. Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis. *Semin Liv Dis* 2005; 25(4): 433-49.
30. Sakaida I, Okita K. The role of oxidative stress in NASH and fatty liver model. *Hep Res* 2005; 33: 128-131.
31. Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGF alpha and collagen type 1 is mediated by oxidative stress through c-myb expression. *J Clin Invest* 1995; 96: 2461-8.
32. Zacharski LR, Chow BK, Howes, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, et al. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. *JAMA* 2007; 297(6): 603-10.
33. Zacharski LR, Shamayeva G, Chow BK. Effect of controlled reduction of body iron stores on clinical outcomes in peripheral arterial disease. *Am Heart J* 2011; 162(5): 949-957.e1.
34. Lambrecht RW, Sterling RK, Naishadham D, Stoddard AM, Rogers T, Morishima C, Morgan TR, Bonkovsky HL; HALT-C Trial Group. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. *Gastroenterol* 2011; 140(5): 1490-500.
35. Kato J, Miyanishi K, Kobune M, Nakamura T, Takada K, Takimoto R. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. *J Gastroenterol* 2007; 42: 830-6.
36. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. *Hepatology* 2010; 51(5): 1820-32.
37. Mascitelli L, Goldstein MR. Metabolic syndrome and liver cancer: is excess iron the link? *Hepatol* 2011; 54(4): 1487.
38. Houglum K, Ramm GA, Crawford DHG, Witzum JL, Powell LW, Chojkier M. Excess iron induces hepatic oxidative stress and transforming growth factor  $\beta$ 1 in genetic hemochromatosis. *Hepatology* 1997; 26(3): 607-10.
39. Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, Vanni E, et al. Iron depletion by phlebotomy improves insulin resistance in patients with non-alcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. *Am J Gastroenterol* 2007; 102: 1251-8.
40. Valenti L, Fracanzani AL, Fargion S. Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance. *Gastroenterology* 2003; 124: 866-7.
41. Valenti L, Moscatello S, Vanni E, Fracanzani AL, Bugianesi E, Fargion S, Marchesini G. Venection for non-alcoholic fatty liver disease unresponsive to lifestyle counseling-a propensity score-adjusted observational study. *QJM* 2011; 104(2): 141-9.